| Lipid Composition for FACG-201 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| L-alpha-Phosphatidylcholine | 0.975 | 0.75 | 65 |
| Cholesterol | 0.435 | 0.17 | 29 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt) | 0.075 | 0.21 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) (NBD PE) | 0.015 | 0.01 | 1 |
| Total | 1.500 µmol/vial | 1.14 mg/vial | 100 |
| Lipid Composition for FACG-202 | Amount (µmol/vial) | Amount (mg/vial) | Molar Ratio Percentage |
|---|---|---|---|
| L-alpha-Phosphatidylcholine | 0.975 | 0.75 | 65 |
| Cholesterol | 0.435 | 0.17 | 29 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt) | 0.075 | 0.21 | 5 |
| 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rhod PE) | 0.015 | 0.02 | 1 |
| Total | 1.500 µmol/vial | 1.15 mg/vial | 100 |
